Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEPVacc: HIV Vaccine and PrEP Efficacy Trial
NCT04066881Phase 2Completed
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DNA-HIV-PT123, AIDSVAX B/E, CN54gp140, MVA-CMDR and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (6 arms), sponsored by MRC/UVRI and LSHTM Uganda Research Unit. Primary endpoints: Incident HIV infection (Vaccine Analysis), Incident HIV infection (PrEP Analysis) and 1 more. Started Dec 2020; status: completed.
02
Drugs
DNA-HIV-PT123AIDSVAX B/ECN54gp140MVA-CMDRtenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04066881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066881.